Skip to main content
  • rainbow over text: 'thank you NHS'
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Allogene Therapeutics Inc (ALLO) COM USD0.001

Sell:$46.00 Buy:$48.00 Change: $1.62 (3.48%)
Market closed |  Prices as at close on 29 May 2020 | Switch to live prices |
Change: $1.62 (3.48%)
Market closed |  Prices as at close on 29 May 2020 | Switch to live prices |
Change: $1.62 (3.48%)
Market closed |  Prices as at close on 29 May 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.

Contact details

210 E Grand Ave
United States
+1 (650) 4572700

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$6.19 billion
Shares in issue:
125.33 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Arie Belldegrun
    Executive Chairman of the Board
  • David Chang
    President, Chief Executive Officer, Co-Founder, Director
  • Joshua Kazam
    Co-Founder, Director
  • Eric Schmidt
    Chief Financial Officer
  • Rafael Amado
    Executive Vice President - Research and Development, Chief Medical Officer
  • Alison Moore
    Chief Technical Officer
  • Veer Bhavnagri
    Chief Compliance Officer, General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.